Interim Report, Q2 and H1 2014
CORTENDO REPORTS RESULTS AND ACTIVITIES FOR THE Q2 AND H1 OF 2014 HIGHLIGHTS - H1’2014 AND POST PERIOD · First patient enrolled into the NormoCort™ Phase 3 SONICS trial - continued progress on trial implementation.The internal and external NormoCort development team has been further strengthened · Matthew Pauls recruited as new CEO – effective Aug 25 · Strategic review to further strengthen focus on orphan drugs and metabolic disease · Net loss for the Group was SEK 8.6 (5.6) million in Q2’2014 (Q2’2013) and SEK 19.8 (9.7) million in H1’2014 (H1’2013), reflecting increased